However, evidence of microtubular defects linked to increased STMN2 expression was shown also in SOD1-ALS, in vivo models, suggesting that dysregulation of STMN2 might be the common, final pathway of neurodegeneration in ALS, independent from TDP-43 pathology. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.